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Gastric cancer is the second leading cause of cancer-related deaths worldwide. In advanced and metastatic gastric cancer, the conven-
tional chemotherapy with limited efficacy shows an overall survival period of about 10 months. Patient specific and effective treatments 
known as personalized cancer therapy is of significant importance. Advances in high-throughput technologies such as microarray and 
next generation sequencing for genes, protein expression profiles and oncogenic signaling pathways have reinforced the discovery of 
treatment targets and personalized treatments. However, there are numerous challenges from cancer target discoveries to practical clini-
cal benefits. Although there is a flood of biomarkers and target agents, only a minority of patients are tested and treated accordingly. Nu-
merous molecular target agents have been under investigation for gastric cancer. Currently, targets for gastric cancer include the epider-
mal growth factor receptor family, mesenchymal-epithelial transition factor axis, and the phosphatidylinositol 3-kinase–AKT–mammalian 
target of rapamycin pathways. Deeper insights of molecular characteristics for gastric cancer has enabled the molecular classification 
of gastric cancer, the diagnosis of gastric cancer, the prediction of prognosis, the recognition of gastric cancer driver genes, and the dis-
covery of potential therapeutic targets. Not only have we deeper insights for the molecular diversity of gastric cancer, but we have also 
prospected both affirmative potentials and hurdles to molecular diagnostics. New paradigm of transdisciplinary team science, which is 
composed of innovative explorations and clinical investigations of oncologists, geneticists, pathologists, biologists, and bio-informaticians, 
is mandatory to recognize personalized target therapy.
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Introduction
The personalized cancer therapy target aberrations that drive 
tumor growth and survival, by administering the right drug combi-
nation for the right person. Advances in high-throughput technol-
ogies such as microarray and next generation sequencing for gene 
or protein expression profiles and oncogenic signaling pathways 
have reinforced the discovery of treatment targets and predictive 
biomarkers. Because of the dramatic advances in genome-scale 
technologies and analytical tools, the personalized cancer therapy 
has been attracted oncologists’ attention since the 2000s. To exploit 
informative biomarker is also obligatory to develop target treat-
ment.1 The DNA-based markers include mutations, single nucleo-
tide polymorphisms (SNPs), chromosomal aberrations, changes 
in DNA copy number, differential methylation. The RNA-based 
biomarkers include overexpressed or underexpressed transcripts 
and microRNAs. The protein markers include growth factors, cell 
surface receptors, phosphorylation states, and peptides released 
by tumors into serum. In 1990s, the Human Genome Project that 
firstly sequenced a human genome, consumed $2,700,000,000 and 
was completed after 15 years,2 however, only $1,000 whole genome 
sequencing is currently available. The era of personal genome se-
quencing has accelerated personalized target treatment (Fig. 1). 
Cho JY
130
However, there are numerous challenges from cancer target dis-
covery to practical clinical benefit. Though the flood of biomarkers 
and target agents, only a minority of patients are tested for bio-
markers and treated accordingly.
Gastric cancer is the second leading cause of cancer-related 
deaths worldwide.3 Surgery is the only curative treatment strategy 
and conventional chemotherapy has shown limited efficacy for 
advanced gastric cancer showing an overall survival of about 10 
months. Gastric cancer is a highly heterogeneous disease where 
even similar clinical and pathologic features,4 and there are various 
endogenous and exogenous causes. Helicobacter pylori infection is 
important exogenous causes for intestinal type of gastric cancer and 
influences the phenotype differences of gastric cancer.5,6 Germline 
mutations and deletions of E-cadherin (CDH1) are the underly-
ing genetic defect in 45% of hereditary diffuse gastric cancer.7 
Many genetic polymorphisms are also found to be associated with 
predisposition to gastric cancer development, including cyclin D1, 
epidermal growth factor receptor (EGFR), p16INK4A, p21WAF1/
CIP1, prostate stem cell antigen, etc.8
Recently, molecular subtypes of gastric cancer have been sug-
gested through analysis of gene or protein expression profiles and 
oncogenic signaling pathways.9-14 The molecular diversity causes 
clinical heterogeneity. Though gastric cancers are molecular bio-
logically heterogeneous disease, treatment strategy is generally 
determined by clinical stage without considering molecular charac-
teristics. Detailed molecular characterization of the patient’s tumor 
will enable tailored therapies to improve outcomes and decrease 
toxicity.
Trastuzumab, a monoclonal antibody against human EGFR 2 
(HER2; also known as ERBB2) is the firstly approved molecular 
target agent for gastric cancer. In Trastuzumab for Gastric Cancer 
(ToGA) trial, 594 patients with gastric cancer showing overexpres-
sion of HER2 protein were randomly assigned to chemotherapy 
(capecitabine/fluorouracil plus cisplatin) or chemotherapy in com-
bination with trastuzumab.15 Trastuzumab extended median over-
all survival from 11.1 months to 13.8 months (hazard ratio [HR] 
0.74; P=0.0046). ToGA trial satisfacted primary objective and was 
referenced in the guideline for cancer treatment (National Com-
prehensive Cancer Network guideline). On the other hand, another 
phase III, randomized clinical trial evaluated the clinical benefit of 
bevacizumab, a monoclonal antibody against vascular endothelial 
growth factor-A, in 770 gastric cancer patients without consider-
ing biomarker.16 The AVAGAST study showed that adding beva-
cizumab to chemotherapy in patients with advanced gastric cancer 
improved progression-free survival and tumor response rate but 
not overall survival (12.1 vs. 10.1 months; HR 0.87; P=0.1002). The 
lesson from the two studies is that identifying tumors most sensitive 
to target agent is requisite to realize personalized target treatment. 
Fig. 1. Fitting the cancer treatment to 
different patients genome.
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Molecular Targets and Clinical Trials 
in Gastric Cancer
Advances in high-throughput cancer genome sequencing, 
genome-wide profiling technologies, and clinical proof-of-con-
cept, are affecting the development and approval of target agents. 
Multiple key regulatory signaling pathways have been identified as 
key drivers of cancer through genetic and epigenetic aberrations. 
For gastric cancer, key drivers include EGFR family, fibroblast 
growth factor receptor (FGFR), hepatocyte growth factor (HGF) 
mesenchymal-epithelial transition factor (c-MET) axis, and the 
phosphatidylinositol 3-kinase (PI3K) AKT mammalian target of 
rapamycin (mTOR) and RAS/RAF/MEK/mitogen-activated pro-
tein kinase pathways (Fig. 2). EGFR family includes EGFR (ErbB1), 
ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4). The activated 
EGFR family consequently stimulates cell proliferation. EGFR 
overexpression has been reported in 30~50% of gastric cancer and 
correlated with poor prognosis.17 HER2 overexpression, appearing 
in 6~35% of gastric cancer, was also associated with poor clinical 
outcome,18 however, the high rate of intratumoral heterogeneity of 
HER2 expression in gastric cancer should be considered to predict 
prognosis.19 The c-MET was overexpression in 10~40% gastric 
cancer and activates proliferation and invasion of cancer cells after 
binding to HGF.20,21 Aberrant FGFR accelerates cancer growing 
and especially FGFR2 was reported to be amplified in 9% of gas-
tric cancer.22 The activation of PI3K/AKT/mTOR signaling path-
way is correlated with poor prognostic cancer and has been studied 
as a treatment target.23 Angiogenesis plays an important role in 
cancer development, growth, and survival, and VEGFs and recep-
tors have been spotlighted as treatment targets. Histone deacety-
lase24 and Poly (ADP-ribose) polymerase (PARP; a family of 
proteins involved in a number of cellular processes involving DNA 
repair and programmed cell death) also have been investigated as 
treatment targets of gastric cancer.25
Up to date, numerous phase 2/3 trials have evaluated molecular 
target agents for gastric cancer (Fig. 2) and phase 3 trials were listed 
in Table 1.15,16,26-30 Table includes not only completed trials, but also 
still recruiting or unpublished trials. As shown in table, the clini-
cal benefit of target agents were demonstrated in only limited trials 
for trastuzumab and ramucirumab. Furthermore, only a few trials 
investigated biomarker for inclusion. Because the survival benefit 
of several target agents was not demonstrated, researchers have 
strained to search for predictive biomarker retrospectively.31
Molecular Diagnostic Approaches Using 
Genome Sequencing and Genome-Wide 
Profiling Technologies for Gastric Cancer 
Deeper insight into molecular characteristics of gastric cancer 
has enabled the molecular classification of gastric cancer, the diag-
nosis of gastric cancer, the prediction of prognosis, the recognition 
of gastric cancer driver genes, and the discovery of potential thera-
peutic targets.
Since 2000s, the gene expression profile analysis of gastric can-
Fig. 2. Target agents for cellular signal-
ing pathway in gastric cancer. HGF = 
hepatocyte growth factor; MET = mes-
enchymal-epithelial transition; EGFR 
= epidermal growth factor receptor; 
FGFR = fibroblast growth factor recep-
tor; VEGFR = vascular endothelial 
growth factor receptor.
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cer has been performed in relatively large sample size.11 The gene 
expression patterns in 90 primary gastric cancers, 14 metastatic 
gastric cancers, and 22 non-neoplastic gastric tissues were analyzed 
using cDNA microarrays representing about 30,300 genes. Gastric 
cancers were distinguished from non-neoplastic gastric tissues by 
characteristic gene expression patterns (2,565 genes; p≤0.001, false 
discovery rate 0.13%). The expression level IGF-2 and PLA2G2A 
were significantly correlated with patient survival. There was a 
diversity of gene expression patterns in gastric cancer, reflecting 
variation in properties of tumor as it is called heterogeneity.
It was suggested that distinct gastric cancer subtypes may be 
distinguished by gene expression analysis.32 Gastric cancer may be 
classified into 3 distinct subtypes–proximal, diffuse, and distal gas-
tric cancer–based on histopathologic and anatomic criteria. From 
36 patients with gastric cancer, 4~6 targeted biopsies of the primary 
tumor were obtained. Macrodissection was carried out and HG-
U133A GeneChip (Affymetrix, Santa Clara, CA, USA) was used 
for cDNA expression analysis. Using supervised analysis, a classi-
fier was built to distinguish the 3 gastric cancer subtypes. Gene set 
analysis identified several pathways that were differentially regulated 
in each gastric cancer subtype. These preliminary data suggested a 
new classification of gastric cancer for improving our understand-
Table 1. Recent phase III clinical trials investigating target agents for gastric cancer
Clinical trial Biomarker Patient (n) Result
Achievement of primary 
objective (reference)
HER2 inhibitor
Capecitabine/cisplatin±trastuzumab (ToGA) HER2 584 PFS 6.7 vs. 5.5, P=0.0002
OS 13.8 vs.11.1, P=0.0046
Positive (15)
Capecitabine/oxaliplatin±lapatinib (LOGiC) HER2 545 Enrollment done NP (NCT00680901)
Paclitaxel±lapatinib (TYTAN) HER2 261 OS 11.3 vs. 8.8, P=0.2088 Negative (26)
EGFR inhibitor
Capecitabine/cisplatin±cetuximab (EXPAND) NA 904 PFS 5.6 vs. 4.4, P=0.3158
OS 10.7 vs. 9.4, P=0.9547
Increased toxicity
Negative (27)
Epirubicin/oxaliplatin/capecitabine±panitumumab (REAR-3) NA 553 PFS 6.0 vs. 7.4, P=0.068
OS 8.8 vs. 11.3, P=0.013
Increased toxicity
Negative (28)
Angiogenesis pathway inhibitor
Capecitabine/cisplatin±bevacizumab (AVAGAST) NA 774 PFS 6.7 vs. 5.3, P=0.0037
OS 12.1 vs. 10.1, P=0.1002
Negative (16)
Ramucirumab vs. placebo (REGARD) NA 355 PFS 2.1 vs. 1.3, P<0.0001
OS 5.2 vs. 3.8, P=0.0473
Positive (29)
Paclitaxel±ramucirumab (RAINBOW) NA 665 Enrollment done NP (NCT01170663)
Afatinib vs. placebo NA 270 Enrolling NP (NCT01512745)
MET/HGF pathway inhibitor
Epirubicin/cisplatin/capecitabine±rilotumumab 
(RILOMET-1)
MET 450 Enrolling NP (NCT01697072)
Fluorouracil/folinic acid/oxaliplatin±onartuzumab 
(MetGastric)
MET
HER2
800 Enrolling NP (NCT01662869)
PI3K/AKT/mTOR pathway inhibitor
Everolimus vs. placebo (GRANITE-1) NA 648 PFS 1.68 vs. 1.41, P<0.0001
OS 5.39 vs. 4.34, P=0.1244
Negative (30 )
Paclitaxel±everolimus (AIO-STO-0111) NA 480 Enrolling NP (NCT01248403)
ToGA = Trastuzumab for Gastric Cancer; PFS = progression free survival; OS = overall survival; NP = not published; NCT = ClinicalTrials.gov 
Identifier; EGFR = epidermal growth factor receptor; NA = not applicable; MET = mesenchymal-epithelial transition factor; HGF = hepatocyte 
growth factor. 
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ing of disease biology and identification of unique molecular drivers 
for each gastric cancer subtype.
The practical biomarker predicting relapse of gastric cancer after 
surgical treatment was investigated.33 Microarray technologies (Hu-
manHT-12 Expression BeadChip; Illumina, San Diego, CA, USA) 
were used to generate and analyze gene expression profiling data 
from 65 gastric cancer patients. Two subgroups of gastric cancer 
based on different gene expression pattern were strongly associ-
ated with the prognosis. A scoring system based on the expression 
of six genes (CTNNB1, EXOCS3, TOP2A, LBA1, CCL5, and 
LZTR1) was developed and predicted independently the likelihood 
of relapse after curative resection. Prognostic characteristics of the 
risk score may not be sufficient to change current clinical practice. 
However, biomarker study in breast cancer showed that 21-gene 
prognostic marker was approved as predictive marker for standard 
adjuvant chemotherapy.34 Thus, in future study, risk score could 
also be applied to clinical practice of gastric cancer.
To identify the molecular underpinnings of gastric cancer, an 
RNA-sequencing approach (SOLiD whole-transcriptome sequenc-
ing and small RNA-sequencing; Applied Biosystems, Foster City, 
CA, USA) was applied to 24 gastric tumor and 6 noncancerous 
specimens, generating 680 million informative short reads to quan-
titatively characterize the entire transcriptome of gastric cancer.35 
A multilayer analysis was then developed to identify multiple types 
of transcriptional aberrations associated with different stages of 
gastric cancer, including differentially expressed mRNAs, recurrent 
somatic mutations, and key differentially expressed miRNAs. The 
central metabolic regulator AMP-activated protein kinase (AMPK) 
was identified as a potential functional target and translational rel-
evance of AMPK was proved as a potential therapeutic target for 
early-stage gastric cancer in Asian patients. 
Recent exome sequencing (SureSelect Human All Exon Kit v1 
[Agilent Technology, Santa Clara, CA, USA] and Illumina GA-
IIx sequencer [Illumina]) of 15 gastric adenocarcinoma identified 
key tumorigenic events in a subset of gastric cancers.36 Frequently 
mutated genes in the gastric cancer were TP53, PIK3CA, and 
ARID1A and the most enriched biological pathway of the fre-
quently mutated genes was cell adhesion. A prevalence screening 
confirmed mutations in FAT4, a cadherin family gene, in 5% of 
gastric cancers and FAT4 genomic deletions in 4% of gastric tu-
mors. Frequent mutations in chromatin remodeling genes (ARID1A, 
MLL3 and MLL) occurred in 47% of the gastric cancers. ARID1A 
mutations were detected in 8% of tumors, which were associated 
with concurrent PIK3CA mutations and microsatellite instability. In 
functional assays, both FAT4 and ARID1A exert tumor-suppressor 
activity. Somatic inactivation of FAT4 and ARID1A may thus be 
key tumorigenic events in a subset of gastric cancers.
The most prevalent molecular targets in gastric cancer were 
identified through SNP profiling.22 Using Affymetrix SNP 6.0 ar-
rays (Affymetrix), copy number alterations were profiled in 233 
gastric cancers (193 primary tumors, 40 cell lines) and 98 gastric 
non-malignant samples. Twenty two recurrent focal alterations 
(13 amplifications and nine deletions) included both known targets 
(FGFR2, ERBB2) and also novel genes (KLF5, GATA6) in gastric 
cancer. The study identified five distinct gastric cancer subgroups, 
defined by the genomic alterations FGFR2 (9% of tumors), KRAS 
(9%), EGFR (8%), ERBB2 (7%) and MET (4%). This study implies 
that the five gastric cancer subgroups may be potentially treatable 
by target therapies. 
A new class of small non-coding RNAs–microRNAs–are 
composed of 19~25 nucleotides and bind to mRNAs of potentially 
hundreds of genes, resulting in degradation of target mRNAs and 
inhibition of translation. Numerous microRNAs are expressed 
aberrantly and correlate with tumorigenesis, progression, and prog-
nosis of various tumors. Three-hundred fifty-three gastric samples 
were analysed using Ohio State University custom microRNA 
microarray chip (OSU_CCC version 3.0; ArrayExpress [European 
Bioinformatics Institute, Cambridge, UK]).37 In paired samples of 
non-tumour mucosa and cancer, 22 microRNAs were upregulated 
and 13 were downregulated in gastric cancer. The two histological 
subtypes (diffuse and intestinal) of gastric cancer showed different 
microRNA signatures. MiR-125b, miR-199a, and miR-100 were 
progression-related. Low expression of let-7g and miR-433 and 
high expression of miR-214 were associated with unfavourable 
outcome in overall survival. The study suggested that microRNAs 
are useful biomarker for progression and prognosis of gastric can-
cer.
Integrative Analysis of Omics Information 
for Gastric Cancer
We systematically analyzed the expression profiles of mRNA, 
microRNA, and protein simultaneously to identify molecular 
biologic differences between good- and poor-prognosis patient 
subgroups. Array technologies were used to generate about 25,000 
annotated genes, 1,100 microRNA, and 124 protein expression 
profiles of 65 patients with gastric cancer. Unsupervised clustering 
revealed distinctive subtypes with clear differences in overall gene 
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expression patterns.33 Two major subtypes were highly associated 
with prognosis. 2,755 genes displayed a poor prognosis-specific 
gene expression pattern. Subsequently, microRNA expression data 
were compared between two prognostic subtypes and four mi-
croRNAs were uniquely dysregulated (P＜0.05) between two sub-
types. On the other hand, protein expression was highly variable 
compared with mRNA and microRNA expression. The expression 
levels of 48 proteins were significantly distinct (P＜0.05) between 
cancer and non-cancer tissues. Through integrative analysis of 
multiple omics information, we perceived molecular diversity of 
gastric cancer and prospected both affirmative potentials of and the 
hurdles against molecular diagnostics.
Conclusions
The effect of molecular diagnostics is apparent in everywhere of 
cancer research. However, its application to the clinic is still lim-
ited. Although integrative molecular characterization of cancer can 
generate the statistical evidence for new candidate cancer targets for 
therapy and diagnosis, converting these into therapeutic agents and 
biomarkers will require deep insights to the biologic mechanism 
of action. New paradigm of transdisciplinary team science, which 
composed of innovative exploration and clinical investigation of 
oncologists, geneticists, pathologists, biologists, and bioinformati-
cians, is mandatory to realize personalized target therapy.
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